Amylyx Pharma Q3 loss narrows

Reuters

2025/11/06

Amylyx Pharma Q3 loss narrows

Overview

Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income
Company's cash position strengthened by $191 mln public offering, extending runway into 2028
Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026

Outlook

Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026
Topline data from LUCIDITY trial anticipated in Q3 2026
Commercial launch of avexitide anticipated in 2027, if approved

Result Drivers

Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS	Beat	-$0.37	-$0.47 (7 Analysts)
Q3 Net Income	Beat	-$34.39 mln	-$41.60 mln (8 Analysts)
Q3 Operating Income	Beat	-$36.03 mln	-$43.10 mln (9 Analysts)
Q3 Pretax Profit	Beat	-$34.39 mln	-$42.50 mln (6 Analysts)
Q3 Operating Expenses		$36.03 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $19.00, about 30.3% above its November 5 closing price of $13.24

Press Release: ID:nBw1MCSvVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581006725"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581006725\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581006725?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581006725","market":"us","top_or_hot":-1,"title":"Amylyx Pharma Q3 loss narrows","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amylyx Pharma Q3 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income</p></li><li><p>Company's cash position strengthened by $191 mln public offering, extending runway into 2028</p></li><li><p>Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026</p></li><li><p>Topline data from LUCIDITY trial anticipated in Q3 2026</p></li><li><p>Commercial launch of avexitide anticipated in 2027, if approved</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.37</p></td><td><p>-$0.47 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$41.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$36.03 mln</p></td><td><p>-$43.10 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$42.50 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.03 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Inc is $19.00, about 30.3% above its November 5 closing price of $13.24</p></li></ul><p>Press Release: <span>ID:nBw1MCSvVa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharma Q3 loss narrows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharma Q3 loss narrows\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-06 20:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Amylyx Pharma Q3 loss narrows</title></head><body><p><span>Overview</span></p><ul><li><p>Amylyx Q3 net loss narrows, beating analyst expectations for EPS and net income</p></li><li><p>Company's cash position strengthened by $191 mln public offering, extending runway into 2028</p></li><li><p>Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026</p></li><li><p>Topline data from LUCIDITY trial anticipated in Q3 2026</p></li><li><p>Commercial launch of avexitide anticipated in 2027, if approved</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td><p>Beat</p></td><td><p>-$0.37</p></td><td><p>-$0.47 (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$41.60 mln (8 Analysts)</p></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$36.03 mln</p></td><td><p>-$43.10 mln (9 Analysts)</p></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$34.39 mln</p></td><td><p>-$42.50 mln (6 Analysts)</p></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$36.03 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/AMLX\">Amylyx Pharmaceuticals</a> Inc is $19.00, about 30.3% above its November 5 closing price of $13.24</p></li></ul><p>Press Release: <span>ID:nBw1MCSvVa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0KB:1","article_id":"2581006725","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581006725","pubTimestamp":1762431601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Amylyx Pharma Q3 loss narrowsOverviewAmylyx Q3 net loss narrows, beating analyst expectations for EPS and net incomeCompany's cash position strengthened by $191 mln public offering, extending runway i","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AMLX":"Amylyx Pharmaceuticals"},"translate_title":"Amylyx Pharma第三季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":0.9},"content_text":"Amylyx Pharma Q3 loss narrowsOverviewAmylyx Q3 net loss narrows, beating analyst expectations for EPS and net incomeCompany's cash position strengthened by $191 mln public offering, extending runway into 2028Completion of recruitment for Phase 3 LUCIDITY trial expected in Q1 2026OutlookCompany expects to complete recruitment for Phase 3 LUCIDITY trial in Q1 2026Topline data from LUCIDITY trial anticipated in Q3 2026Commercial launch of avexitide anticipated in 2027, if approvedResult DriversResearch and development expenses for the third quarter of 2025 were $19.9 million, compared to $21.2 million for the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPSBeat-$0.37-$0.47 (7 Analysts)Q3 Net IncomeBeat-$34.39 mln-$41.60 mln (8 Analysts)Q3 Operating IncomeBeat-$36.03 mln-$43.10 mln (9 Analysts)Q3 Pretax ProfitBeat-$34.39 mln-$42.50 mln (6 Analysts)Q3 Operating Expenses$36.03 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $19.00, about 30.3% above its November 5 closing price of $13.24Press Release: ID:nBw1MCSvVaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}